二甲双胍联合甲钴胺治疗DPNP患者的临床疗效及对患者神经传导速度的影响

doi:10.3969/j.issn.1671-7171.2025.05.014

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1187 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical efficacy of metformin combined with mecobalamin in treating patients with diabetic peripheral neuropathic pain (DPNP) and its effect on nerve conduction velocity. 【Methods】One hundred DPNP patients admitted to our hospital from July to December 2021 were divided into the control group (50 cases, treated with mecobalamin) and the observation group (50 cases, treated with metformin combined with mecobalamin) using a random number table method. General data, biochemical indicators, Visual Analogue Scale (VAS) scores, nerve conduction velocity, and adverse reactions were compared between the two groups. 【Results】There were no significant differences in gender, age, disease duration, or smoking history between the two groups (P>0.05), and no significant differences in body mass index before treatment or after 12 and 24 weeks of treatment (P>0.05). After 12 and 24 weeks of treatment, fasting plasma glucose (FPG), 2-hour postprandial blood glucose, glycosylated hemoglobin (HbA1c) levels, and VAS scores were lower than those before treatment in both groups, with the observation group showing more significant reductions. Fasting C-peptide (FCP) and 2-hour postprandial C-peptide levels were higher than those before treatment in both groups, with the observation group showing higher levels (P<0.05). The motor nerve conduction velocity (MCV) and sensory nerve conduction velocity (SCV) of the tibial and peroneal nerves were higher than those before treatment in both groups after 12 and 24 weeks of treatment, with the observation group showing faster velocities (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Metformin combined with mecobalamin can significantly reduce blood glucose levels, alleviate pain, and improve nerve conduction velocity in DPNP patients, with safe and controllable medication.

Key words： Diabetic Neuropathies Peripheral Nervous System Diseases Metformin Treatment Outcome

Received: 16 October 2024

PACS:

R587.25

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Yuanting

Cite this article:

ZHOU Yuanting. Clinical Efficacy of Metformin Combined with Mecobalamin in Treating DPNP Patients and its Impact on Nerve Conduction Velocity[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(5): 784-787.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.05.014 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I5/784

[1] II J C L, LULLOVE E J, LIDEN B, et al. Final efficacy and cost analysis of a fish skin graft vs standard of care in the management of chronic diabetic foot ulcers: a prospective, multicenter, randomized controlled clinical trial[J].Wounds,2023,35(4):71-79.
[2] ELAFROS M A, ANDERSEN H, BENNETT D L, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments[J].Lancet Neurol,2022,21(10):922-936.
[3] HUANG H, ZHAO M, LIU X Y, et al. Glutathione combined with Mecobalamin in the treatment of chemotherapy-induced peripheral neuropathy in multiple myeloma: a retrospective clinical study[J].Ann Palliat Med,2021,10(12):12335-12346.
[4] 谷宇峰, 潘秀秀, 宋玲, 等. 二甲双胍抑制JNK改善缝隙连接功能缓解骨癌痛的实验研究[J].中国药科大学学报, 2019,50(3):337-343.
[5] ALBERTI K G, ZIMMET P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J].Diabet Med,1998,15(7):539-553.
[6] 孙兵, 车晓明. 视觉模拟评分法(VAS)[J].中华神经外科杂志, 2012,28(6):645.
[7] ABU-SHENNAR J A, BAYRAKTAR N. The effect of educational program on pain management, self-efficacy behavior, and quality of life among adult diabetic patients with peripheral neuropathy pain: a randomized controlled trial[J].Exp Clin Endocrinol Diabetes,2022,130(8):509-518.
[8] 吕春卉, 李大炜, 王小洁, 等. 二甲双胍联合辛伐他汀治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J].实用肝脏病杂志, 2022,25(1):50-53.
[9] KANG S M, YUN H M, SOHN M J, et al. Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study[J].Diabetes Obes Metab,2023,25(7):1922-1931.
[10] 吴昀. 木丹颗粒联合常规西药治疗糖尿病周围神经病变对神经传导速度的影响及疗效观察[J].辽宁中医杂志, 2021,48(1):112-115.
[11] 李欣媛, 张涵涛. 甲钴胺用于糖尿病周围神经病变临床治疗中改善神经传导功能的效果[J].检验医学与临床, 2021,18(10):1488-1491.
[12] 马朋朋, 董聪慧, 李伟, 等. 尼可地尔片联合二甲双胍缓释片治疗糖尿病足周围神经病变的临床研究[J].中国临床药理学杂志, 2019,35(5):421-424.
[13] 孙勇, 刘武, 张维, 等. 二甲双胍对2型糖尿病并发神经病理性疼痛大鼠的抗痛觉异常作用及机制研究[J].中华神经医学杂志, 2021,20(12):1194-1203.